Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

    April 2023 in “ The Lancet ”
    Brett King, Xingqi Zhang, Walter Gubelin Harcha … Robert Wołk
    Studysummary Ritlecitinib effectively treats alopecia areata and is well-tolerated.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on escholarship.org →
    Discuss this study in the Community →

    Research cited in this study 19

    1. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    2. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    3. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    4. Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata JCI insight · 2021
    5. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    6. ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata Journal of Patient-Reported Outcomes · 2020
    7. Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata Experimental dermatology · 2020
    8. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020
    9. Assessment of a Bidirectional Association Between Major Depressive Disorder and Alopecia Areata JAMA Dermatology · 2019
    10. Monotherapy for Alopecia Areata: A Systematic Review and Network Meta-Analysis Skin appendage disorders · 2019
    11. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    12. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    13. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    14. Multiplex Matrix Network Analysis of Protein Complexes in the Human TCR Signalosome Science Signaling · 2016
    15. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    16. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012
    17. Alopecia: Evaluation and Treatment Clinical, Cosmetic and Investigational Dermatology · 2011
    18. Interventions for Alopecia Areata Journal of Evidence-Based Medicine · 2009
    19. Lymphocytes, Neuropeptides, And Genes Involved In Alopecia Areata Journal of Clinical Investigation · 2007

    Related research 4

    1. Case Report of Novel Combination of Anthralin and Calcipotriene Leading to Trichologic Response in Alopecia Areata JAAD case reports · 2019
    2. Alopecia Areata: A Multifactorial Autoimmune Condition Journal of autoimmunity · 2018
    3. Linear Alopecia Areata JAAD case reports · 2018
    4. Treating Resistant Cases of Alopecia Universalis Journal of cosmetology & trichology · 2018